Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 Market Cap is $20.60 Mil as of Sep. 13, 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,419 Biotechnology companies, Psyence Biomedical ranks worse than 76.11% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Psyence Biomedical's share price for the quarter that ended in Mar. 2026 was $2.46. Psyence Biomedical's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.29 Mil. Therefore, Psyence Biomedical's market cap for the quarter that ended in Mar. 2026 was $5.64 Mil.
Psyence Biomedical's quarterly market cap
increased
from Mar. 2025 ($2.72 Mil) to Sep. 2025 ($6.00 Mil) but then
declined
from Sep. 2025 ($6.00 Mil) to Mar. 2026 ($5.64 Mil).
Psyence Biomedical's annual market cap
declined
from Mar. 2024 ($17.04 Mil) to Mar. 2025 ($2.72 Mil) but then
increased
from Mar. 2025 ($2.72 Mil) to Mar. 2026 ($5.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Psyence Biomedical's Enterprise Value for Today is $21.17 Mil.
Psyence Biomedical (NAS:PBM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Psyence Biomedical Market Cap Related Terms
Psyence Biomedical Market Cap Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Psyence Biomedical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Market Cap distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Psyence Biomedical's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psyence Biomedical (PBM) has a Market Cap of $20.60 Mil as of Sep. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #1080 out of 1419 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Psyence Biomedical's Market Cap too high?
Psyence Biomedical's current Market Cap is $20.60 Mil. The Biotechnology industry median Market Cap is 117.60. Psyence Biomedical's value of $20.60 Mil is 82.5% below this industry median. Based on the distribution chart, Psyence Biomedical ranks #1080 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Market Cap compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #1080 out of 1419 companies for Market Cap. This places Psyence Biomedical in the lower half of its industry. The industry median Market Cap is 117.60. Psyence Biomedical's value of $20.60 Mil is 82.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.60, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Psyence Biomedical's current Market Cap of $20.60 Mil is 82.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Psyence Biomedical and its competitors. For the Biotechnology industry, the median Market Cap is 117.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current Market Cap is $20.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Market Cap of $20.60 Mil. The current Market Cap is $20.60 Mil and 82.5% below the Biotechnology industry median of 117.60. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Market Cap is $20.60 Mil as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
